Polyclonal Antibodies Market Size & Share, by Type (Human Source, Animal Source); End Users (Hospitals, Diagnostic Laboratories, Biotechnology Companies); Source (Rabbit, Goat, Mouse, Sheep); Product Type (Primary Antibody, Secondary Antibody), Application (Hepatitis Diagnostics, Tuberculosis Diagnostics, Cancer Diagnostics, Oncology Diagnostics, HIV Diagnostics, Infectious Disease Diagnostics)- Global Supply & Demand Analysis, Growth Forecasts, Statistics Report 2024-2036

  • Report ID: 5659
  • Published Date: Apr 29, 2024
  • Report Format: PDF, PPT

Global Market Size, Forecast, and Trend Highlights Over 2024-2036

Polyclonal Antibodies Market size is poised to reach USD 26 Billion by the end of 2036, growing at a CAGR of 8% during the forecast timeframe, i.e., 2024-2036. In the year 2023, the industry size of the polyclonal antibodies revenue share was USD 10 Billion. The market expansion is due to the projected need for therapeutic applications, as polyclonal antibodies find extensive use in therapeutic applications, notably in the development of antivenom and immunoglobulin therapies, which can help in preventing hemolytic disease in newborns while modifying inflammatory reactions.

According to a report, about 25% of newborns suffer from hemolytic disease of the newborns (HDN), which requires transfusion. Due to this, this industry is expected to witness a substantial growth rate in the forecasted years.

In addition, adopting polyclonal antibodies is particularly important in cases where the multifaceted nature of diseases necessitates a comprehensive immune response. For instance, in antivenom therapy, polyclonal antibodies are harnessed to neutralize the venom components of various snake species effectively.

Polyclonal Antibodies Market
Get more information on this report: Request Free Sample PDF

Polyclonal Antibodies Sector: Growth Drivers and Challenges

Growth Drivers

  • Technological advancements in antibody production - The continuous evolution of polyclonal antibody production technologies, along with several technological advancements, has lucratively improved the efficiency and demand of manufacturing processes while ensuring a consistent supply of high-quality polyclonal antibodies to consumers. According to a report, in the U.S., more than 24 million people are affected by more than 80 different types of autoimmune diseases. Moreover, innovations in antibody purification, expression systems, production platforms, and many more have streamlined their manufacturing procedures while reducing production costs and improving overall product quality. This has had a substantial effect on market growth as pharmaceutical and biotechnology companies are increasingly turning towards advanced technologies for the development and production of polyclonal antibodies. In addition, the increasing incidence of diseases such as rheumatoid arthritis, lupus, and multiple sclerosis has led to a surge in research and development activities that are focused on the demand for polyclonal antibodies for effective treatment. According to the American Autoimmune Related Diseases Association (AARDA), approximately 50 million Americans suffered from autoimmune diseases as of 2021.
  • Increase in cancer disease - Since polyclonal antibodies are produced by B cells in response to an antigen, such as malignant cells, the market share for these antibodies is slated to expand at a lucrative rate, which can be attributed to the rise in cancer cases. According to a report, there were about 20 million new cancer cases in 2022 and about 9.7 million deaths caused by cancer. Furthermore, driven by the disease's global rise, there is a strong need for both accurate and effective cancer treatments as well as diagnostics. The production of high-quality antibodies in large quantities has also become easier and more economical with the advent of new technology for the production and purification of polyclonal antibodies. This has increased the range of polyclonal antibodies for clinical as well as research applications, which has further fueled market demand.
  • Research and development in life sciences - The ongoing advancements in life sciences research contribute substantially to the growth of the polyclonal antibodies market. Polyclonal antibodies play a crucial role in various research applications, such as Western blotting, immunohistochemistry, and flow cytometry. The expanding scope of life sciences research, including genomics, proteomics, and cell biology, demands reliable and versatile tools like polyclonal antibodies. This increasing demand for antibodies in research applications fuels the growth of the market, with academic institutions, research laboratories, and biotechnology companies actively contributing to the expanding landscape.


  • Availability of different options - Polyclonal antibodies, which are derived from the immune responses of multiple organisms, can lead to several differences in the antibody composition, and this variability can highly impact the reproducibility and consistency of such experimental results. This can pose many challenges in research and diagnostic applications.Furthermore, the dominance of monoclonal antibodies in certain therapeutic and diagnostic applications poses a challenge for the polyclonal antibody landscape. Monoclonal antibodies also offer a much more targeted approach, coupled with higher specificity and reduced variability compared to polyclonal antibodies. This can act as a restraining factor for the growth rate of this sector.
  • High competition from monoclonal antibodies can cause hindrance.
  • Increasing ethical and regulatory concerns

Polyclonal Antibodies Market: Key Insights

Base Year


Forecast Year




Base Year Market Size (2023)

USD 10 Billion

Forecast Year Market Size (2036)

USD 26 Billion

Regional Scope

  • North America (U.S., and Canada)
  • Asia-Pacific (Japan, China, India, Indonesia, Malaysia, Australia, Rest of Asia-Pacific)
  • Europe (U.K., Germany, France, Italy, Spain, Russia, NORDIC, Rest of Europe)
  • Latin America (Mexico, Argentina, Rest of Latin America)
  • Middle East and Africa (Israel, GCC North Africa, South Africa, Rest of the Middle East and Africa)
Get more information on this report: Request Free Sample PDF

Polyclonal Antibodies Segmentation

Type (Human Source, Animal Source)

The human source segment in the polyclonal antibodies market is estimated to gain revenue of about 54% by 2036. The segment influence can be attributed to the pursuit of enhanced immunogenicity and specificity, as human-derived antibodies have a natural advantage in clinical and therapeutic applications as they are less likely to provoke an immune response when tested on humans.

Additionally, this characteristic is particularly crucial in therapeutic interventions, ensuring greater safety and reducing the risk of adverse reactions. Human-derived polyclonal antibodies offer reduced cross-reactivity and improved safety profiles, making them increasingly attractive for therapeutic use. Cross-reactivity, often encountered with animal-derived antibodies, can lead to unintended side effects.

By sourcing antibodies from humans, the likelihood of unwanted interactions and adverse events is minimized, aligning with the stringent safety requirements in clinical settings. The increasing emphasis on personalized medicine has emerged as a significant growth driver for human-sourced polyclonal antibodies.

End Users (Hospitals, Diagnostic Laboratories, Biotechnology Companies)

The hospital segment in the polyclonal antibodies market is expected to garner a tremendous share by the end of 2036. As polyclonal antibodies are highly used in hospitals for therapeutic purposes, particularly in immunotherapy, because they play a crucial role in modulating immune responses, this makes them a valuable component in the treatment of various diseases, including certain cancers and autoimmune disorders. The application of polyclonal antibodies in immunotherapy widens the therapeutic options available to hospitals for managing complex medical conditions.

A clinical trial review reported a 30% improvement in overall response rates in cancer patients treated with immunotherapies incorporating polyclonal antibodies. Advancements in point-of-care testing within hospitals are facilitated by the use of polyclonal antibodies. The rapid and reliable results obtained through point-of-care tests contribute to timely diagnosis and treatment decisions. The flexibility of polyclonal antibodies in various testing formats enhances their applicability in point-of-care settings, supporting hospitals in providing efficient and patient-centric healthcare services.

Our in-depth analysis of the global polyclonal antibodies market includes the following segments:


  • Human Source
  • Animal Source


  • Hospitals
  • Diagnostic Laboratories
  • Biotechnology Companies


  • Rabbit
  • Goat
  • Mouse
  • Sheep

          Product Type

  • Primary Antibody
  • Secondary Antibody


  • Hepatitis Diagnostics
  • Tuberculosis Diagnostics
  • Cancer Diagnostics
  • Oncology Diagnostics
  • HIV Diagnostics
  • Infectious Disease Diagnostics

Want to customize this research report as per your requirements? Our research team will cover the information you require to help you take effective business decisions.

Customize this Report

Polyclonal Antibodies Industry - Regional Synopsis

APAC Market Forecast

The polyclonal antibodies market in the Asia Pacific region is set to hold the largest share of about 47% by the end of 2036. This sector is poised to propel in the region and is expected to drive on account of the extensive use of polyclonal antibodies in immunohistochemistry (IHC), a technique crucial for the examination of tissue samples. Hospitals leverage IHC for the diagnosis of various cancers and pathological conditions.

Moreover, the versatility of polyclonal antibodies in recognizing multiple antigens makes them invaluable in IHC applications, enabling hospitals to obtain comprehensive and detailed information from tissue specimens. Polyclonal antibodies play a crucial role in hospitals during infectious disease outbreaks. They are utilized for the rapid development of diagnostic tests and potential therapeutic interventions. During the Zika virus outbreak, hospitals incorporating polyclonal antibodies in diagnostic assays reported a 20% faster identification of infected individuals compared to hospitals using alternative testing methods.

North American Market Statistics

The North American region will also encounter a huge impact on the polyclonal antibodies market size expansion in the coming years and will hold the second position owing to the rising prevalence of chronic diseases such as cancer, cardiovascular diseases, and autoimmune disorders, which would drive the need for advanced diagnostic tools and targeted therapeutic interventions, where polyclonal antibodies will find extensive applications.

Research Nester
Polyclonal Antibodies Market Size
Get more information on this report: Request Free Sample PDF

Companies Dominating the Polyclonal Antibodies Landscape

    • Abcam plc
      • Company Overview
      • Business Strategy
      • Key Product Offerings
      • Financial Performance
      • Key Performance Indicators
      • Risk Analysis
      • Recent Development
      • Regional Presence
      • SWOT Analysis
    • Thermo Fisher Scientific Inc.
    • Merck KGaA
    • Bio-Rad Laboratories, Inc.
    • GenScript Biotech Corporation
    • BioLegend, Inc.
    • Cell Signaling Technology, Inc.
    • Rockland Immunochemicals Inc.
    • Agilent Technologies, Inc.
    • Fitzgerald Industries International

In the News

  • Xenothera- announced their recent evidence which supports the importance of using glycol-humanized polyclonal antibody XAV-19 for treating patients during the initial viral phase of the disease.
  • Merck and Kelun-Biotech- announced the seven different exploratory preclinical antibody-drug conjugates, especially for cancer treatment.

Author Credits:  Radhika Gupta, Shivam Bhutani

  • Report ID: 5659
  • Published Date: Apr 29, 2024
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

In the year 2023, the industry size of barge transportation was over USD 10 Billion.

The market size for the polyclonal antibodies market is projected to cross USD 26 Billion by the end of 2036 expanding at a CAGR of 8% during the forecast period i.e., between 2024-2036.

The major players in the market are Thermo Fisher Scientific Inc., Merck KGaA, Bio-Rad Laboratories, Inc., GenScript Biotech Corporation, BioLegend, Inc., Cell Signaling Technology, Inc., Rockland Immunochemicals Inc., Agilent Technologies, Inc., Fitzgerald Industries International, Fujifilm Corporation, Wako Pure Chemical Industries, Ltd., Cosmo Bio Co., Ltd., MBL International Corporation, Abnova Corporation., and others.

In terms of type, the human source segment is anticipated to account for the largest market share of 54% during 2024-2036.

The Asia Pacific polyclonal antibodies sector is poised to hold the highest share of 47% by 2036.
Polyclonal Antibodies Market Report Scope

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying